Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2001 1
2003 1
2004 1
2005 1
2006 1
2007 3
2008 1
2010 1
2012 1
2013 2
2014 2
2015 3
2016 6
2017 2
2018 4
2019 5
2020 6
2021 3
2022 4
2023 5
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

46 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial.
Platzbecker U, Della Porta MG, Santini V, Zeidan AM, Komrokji RS, Shortt J, Valcarcel D, Jonasova A, Dimicoli-Salazar S, Tiong IS, Lin CC, Li J, Zhang J, Giuseppi AC, Kreitz S, Pozharskaya V, Keeperman KL, Rose S, Shetty JK, Hayati S, Vodala S, Prebet T, Degulys A, Paolini S, Cluzeau T, Fenaux P, Garcia-Manero G. Platzbecker U, et al. Lancet. 2023 Jul 29;402(10399):373-385. doi: 10.1016/S0140-6736(23)00874-7. Epub 2023 Jun 10. Lancet. 2023. PMID: 37311468 Clinical Trial.
Integrated response technology was used to randomly assign patients (1:1, block size 4) to luspatercept or epoetin alfa, stratified by baseline red blood cell transfusion burden (<4 units per 8 weeks vs 4 units per 8 weeks), endogenous serum erythropoietin concentration (200 U …
Integrated response technology was used to randomly assign patients (1:1, block size 4) to luspatercept or epoetin alfa, stratified by basel …
Long-term utilization and benefit of luspatercept in transfusion-dependent, erythropoiesis-stimulating agent-refractory or -intolerant patients with lower-risk myelodysplastic syndromes with ring sideroblasts.
Platzbecker U, Santini V, Komrokji RS, Zeidan AM, Garcia-Manero G, Buckstein R, Miteva D, Keeperman K, Holot N, Nadal JA, Lai Y, Vodala S, Rosettani B, Giuseppi AC, Yucel A, Fenaux P. Platzbecker U, et al. Leukemia. 2023 Nov;37(11):2314-2318. doi: 10.1038/s41375-023-02031-7. Epub 2023 Sep 26. Leukemia. 2023. PMID: 37752285 Free PMC article. No abstract available.
Long-Term Efficacy and Safety of Luspatercept for Anemia Treatment in Patients With Lower-Risk Myelodysplastic Syndromes: The Phase II PACE-MDS Study.
Platzbecker U, Götze KS, Kiewe P, Germing U, Mayer K, Radsak M, Wolff T, Chromik J, Sockel K, Oelschlägel U, Haase D, Illmer T, Al-Ali HK, Silling G, Reynolds JG, Zhang X, Attie KM, Shetty JK, Giagounidis A. Platzbecker U, et al. J Clin Oncol. 2022 Nov 20;40(33):3800-3807. doi: 10.1200/JCO.21.02476. Epub 2022 Aug 23. J Clin Oncol. 2022. PMID: 35998303 Free PMC article. Clinical Trial.
Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.Luspatercept has high clinical activity in patients with transfusion-dependent lower-risk myelody …
Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the p …
Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study.
Platzbecker U, Germing U, Götze KS, Kiewe P, Mayer K, Chromik J, Radsak M, Wolff T, Zhang X, Laadem A, Sherman ML, Attie KM, Giagounidis A. Platzbecker U, et al. Lancet Oncol. 2017 Oct;18(10):1338-1347. doi: 10.1016/S1470-2045(17)30615-0. Epub 2017 Sep 1. Lancet Oncol. 2017. PMID: 28870615 Clinical Trial.
Patient data were subcategorised by: luspatercept dose concentrations (0.125-0.5 mg/kg vs 0.75-1.75 mg/kg); pre-study transfusion burden (high transfusion burden vs low transfusion burden, defined as 4 vs <4 red blood cell units per 8 weeks); pre-study serum erythropoietin con …
Patient data were subcategorised by: luspatercept dose concentrations (0.125-0.5 mg/kg vs 0.75-1.75 mg/kg); pre-study transfusion burden (hi …
Activin Receptor II Ligand Traps and Their Therapeutic Potential in Myelodysplastic Syndromes with Ring Sideroblasts.
Mies A, Hermine O, Platzbecker U. Mies A, et al. Curr Hematol Malig Rep. 2016 Dec;11(6):416-424. doi: 10.1007/s11899-016-0347-9. Curr Hematol Malig Rep. 2016. PMID: 27595736 Review.
Distinct subtypes of lower risk myelodysplastic syndromes display ring sideroblasts in the bone marrow, i. e., erythroid progenitors characterized by excessive iron deposited in the mitochondria. ...
Distinct subtypes of lower risk myelodysplastic syndromes display ring sideroblasts in the bone marrow, i. e., erythroid progenitors …
Setting Fire to ESA and EMA Resistance: New Targeted Treatment Options in Lower Risk Myelodysplastic Syndromes.
Kubasch AS, Platzbecker U. Kubasch AS, et al. Int J Mol Sci. 2019 Aug 7;20(16):3853. doi: 10.3390/ijms20163853. Int J Mol Sci. 2019. PMID: 31394818 Free PMC article. Review.
Luspatercept, a ligand trap of activin receptor II, is able to promote late stage erythropoiesis even in patients failing prior ESA treatment. The presence of ring sideroblastic phenotype defines a subgroup of patients with higher response rates. ...
Luspatercept, a ligand trap of activin receptor II, is able to promote late stage erythropoiesis even in patients failing prior ESA treatmen …
A Stable Bis(benzocyclobutadiene)-Annelated Tetraazapentacene Derivative.
Biegger P, Schaffroth M, Tverskoy O, Rominger F, Bunz UH. Biegger P, et al. Chemistry. 2016 Oct 24;22(44):15896-15901. doi: 10.1002/chem.201602675. Epub 2016 Sep 15. Chemistry. 2016. PMID: 27628243
To achieve the title compound, the biphenylenedione is coupled with a diaminobenzothiadiazole derivative. Reductive cleavage of the thiadiazole ring and subsequent condensation with the biphenylenedione gives the title compound in which a central tetraazapentacene is flank …
To achieve the title compound, the biphenylenedione is coupled with a diaminobenzothiadiazole derivative. Reductive cleavage of the thiadiaz …
Diagnostics and early treatment in prehospital and emergency-room phase in suspicious pelvic ring fractures.
Schweigkofler U, Wohlrath B, Trentsch H, Greipel J, Tamimi N, Hoffmann R, Wincheringer D. Schweigkofler U, et al. Eur J Trauma Emerg Surg. 2018 Oct;44(5):747-752. doi: 10.1007/s00068-017-0860-0. Epub 2017 Oct 12. Eur J Trauma Emerg Surg. 2018. PMID: 29026927
BACKGROUND: Testing for mechanical stability in pelvic ring fractures is advocated for the initial assessment and management of pelvic ring fractures. ...METHODS: We performed a prospective multicenter observational study on patients admitted to the emergency room w …
BACKGROUND: Testing for mechanical stability in pelvic ring fractures is advocated for the initial assessment and management of pelvi …
Bone marrow-independent adventitial macrophage progenitor cells contribute to angiogenesis.
Kleefeldt F, Upcin B, Bömmel H, Schulz C, Eckner G, Allmanritter J, Bauer J, Braunger B, Rueckschloss U, Ergün S. Kleefeldt F, et al. Cell Death Dis. 2022 Mar 9;13(3):220. doi: 10.1038/s41419-022-04605-2. Cell Death Dis. 2022. PMID: 35264563 Free PMC article.
To answer this question, we analyzed vascular sprouting and alterations in aortic cell populations in mouse aortic ring assays (ARA). ARA culture leads to the generation of large numbers of macrophages, especially within the aortic adventitia. ...
To answer this question, we analyzed vascular sprouting and alterations in aortic cell populations in mouse aortic ring assays (ARA). …
46 results